Author details

Full Name

Sandro Santagata

Affiliation

ORCID

Career Start Year

1996

Papers

206

H Index

Expertise

CM4AI Collaborator

PMID	Paper Title	Journal Title	Published Year
37349501	High-plex immunofluorescence imaging and traditional histology of the same tissue section for discovering image-based biomarkers.		2023
36170403	Visinity: Visual Spatial Neighborhood Analysis for Multiplexed Tissue Imaging Data.	IEEE Trans Vis Comput Graph	2023
36227281	Hypermitotic meningiomas harbor DNA methylation subgroups with distinct biological and clinical features.	Neuro Oncol	2023
36288512	Alliance A071401: Phase II Trial of Focal Adhesion Kinase Inhibition in Meningiomas With Somatic <i>NF2</i> Mutations.	J Clin Oncol	2023
37944590	Targeted gene expression profiling predicts meningioma outcomes and radiotherapy responses.	Nat Med	2023
38014110	Cell Spotter (CSPOT): A machine-learning approach to automated cell spotting and quantification of highly multiplexed tissue images.		2023
38014052	Multiplexed 3D Analysis of Cell Plasticity and Immune Niches in Melanoma.		2023
37728381	Genomic analysis of spinal meningiomas: correlation with histopathological grade.		2023
37986801	2D and 3D multiplexed subcellular profiling of nuclear instability in human cancer.		2023
37722087	Inaugural Results of the Individualized Screening Trial of Innovative Glioblastoma Therapy: A Phase II Platform Trial for Newly Diagnosed Glioblastoma Using Bayesian Adaptive Randomization.	J Clin Oncol	2023
37980418	Comprehensive analysis reveals potential therapeutic targets and an integrated risk stratification model for solitary fibrous tumors.		2023
37961235	Quality Control for Single Cell Analysis of High-plex Tissue Profiles using CyLinter.		2023
37870091	Systematic Characterization of Antibody-Drug Conjugate Targets in Central Nervous System Tumors.		2023
37160103	Meet the authors: Dr. Clint Allen and Dr. Sandro Santagata.		2023
37469028	Chemical QuantArray: A Quantitative Tool for Mass Spectrometry Imaging.		2023
37030295	USP9X mediates an acute adaptive response to MAPK suppression in pancreatic cancer but creates multiple actionable therapeutic vulnerabilities.	Cell Rep Med	2023
37450351	Endocrine Therapy Synergizes with SMAC Mimetics to Potentiate Antigen Presentation and Tumor Regression in Hormone Receptor-Positive Breast Cancer.	Cancer Res	2023
37059105	Lymphocyte networks are dynamic cellular communities in the immunoregulatory landscape of lung adenocarcinoma.		2023
37437144	BRAF-MEK Inhibition in Newly Diagnosed Papillary Craniopharyngiomas.	N Engl J Med	2023
36993741	Targeted gene expression profiling predicts meningioma outcomes and radiotherapy responses.	Res Sq	2023
36669472	Multiplexed 3D atlas of state transitions and immune interaction in colorectal cancer.	Cell	2023
37524847	A comprehensive genomic study of 390 H3F3A-mutant pediatric and adult diffuse high-grade gliomas, CNS WHO grade 4.		2023
37491289	Impact of H3K27 trimethylation loss in meningiomas: a meta-analysis.		2023
34750536	Narrative online guides for the interpretation of digital-pathology images and tissue-atlas data.	Nature Biomedical Engineering	2022
35973991	Single cell spatial analysis reveals the topology of immunomodulatory purinergic signaling in glioblastoma.	Nat Commun	2022
35972352	Stitching and registering highly multiplexed whole-slide images of tissues and tumors using ASHLAR.		2022
36173860	Oncometabolite d-2HG alters T cell metabolism to impair CD8<sup>+</sup> T cell function.	Science	2022
36099884	Spatial transcriptomics.	Cancer Cell	2022
36352222	Spatial genomics maps the structure, nature and evolution of cancer clones.	Nature	2022
35617956	A human breast atlas integrating single-cell proteomics and transcriptomics.	Dev Cell	2022
36057740	PD-L1 and PD-1 expression in pediatric central nervous system germ cell tumors.	Modern Pathology	2022
35404441	The Spatial Landscape of Progression and Immunoediting in Primary Melanoma at Single-Cell Resolution.	Cancer Discovery	2022
34015129	Activity of PD-1 blockade with nivolumab among patients with recurrent atypical/anaplastic meningioma: phase II trial results.	Neuro Oncol	2022
34164689	Skull Base Tumors: Neuropathology and Clinical Implications.	Neurosurgery	2022
35298263	Copper induces cell death by targeting lipoylated TCA cycle proteins.	Science	2022
35294249	HSF2 cooperates with HSF1 to drive a transcriptional program critical for the malignant state.	Sci Adv	2022
35292783	Temporal and spatial topography of cell proliferation in cancer.	Nature Cell Biology	2022
35289329	Phase 2 study of pembrolizumab in patients with recurrent and residual high-grade meningiomas.	Nat Commun	2022
34508644	A molecularly integrated grade for meningioma.	Neuro Oncol	2022
34383057	Multimodal platform for assessing drug distribution and response in clinical trials.	Neuro Oncol	2022
35149709	Single-cell tumor-immune microenvironment of BRCA1/2 mutated high-grade serous ovarian cancer.	Nat Commun	2022
34606456	Scope2Screen: Focus+Context Techniques for Pathology Tumor Assessment in Multivariate Image Data.		2022
34824477	MCMICRO: a scalable, modular image-processing pipeline for multiplexed tissue imaging.	Nat Methods	2022
34878541	Clinical utility of targeted next-generation sequencing assay in IDH-wildtype glioblastoma for therapy decision-making.	Neuro Oncol	2022
34534464	Antigen dominance hierarchies shape TCF1<sup>+</sup> progenitor CD8 TÂ cell phenotypes in tumors.	Cell	2021
33738458	Targeting immunosuppressive macrophages overcomes PARP inhibitor resistance in BRCA1-associated triple-negative breast cancer.	Nat Cancer	2021
33579785	Identification and Therapeutic Targeting of GPR20, Selectively Expressed in Gastrointestinal Stromal Tumors, with DS-6157a, a First-in-Class Antibody-Drug Conjugate.	Cancer Discovery	2021
33451979	HAND1 and BARX1 Act as Transcriptional and Anatomic Determinants of Malignancy in Gastrointestinal Stromal Tumor.	Clin Cancer Res	2021
33822195	Prognostication for meningiomas: H3K27me3 to the rescue?	Neuro-Oncology	2021
33407897	Sporadic multiple meningiomas harbor distinct driver mutations.	Acta neuropathologica communications	2021